Exploring Ion Mobility–Mass Spectrometry and CIU Data: An ASMS Interview with Brandon Ruotolo
At ASMS 2023, LCGC spoke with Brandon Ruotolo of the University of Michigan in Ann Arbor. This segment is one of several ASMS interviews that were conducted at the conference.
Ruotolo talked with us at ASMS 2023 in Houston, Texas, where he discussed his recently published Analyst paper on ion mobility-mass spectrometry (IM–MS), the reproducibility of collision-induced unfolding (CIU) data, and the impact his research can have on future biomolecular classification efforts.
Ruotolo is the Associate Chair for Research and a Professor of Chemistry at University of Michigan – Ann Arbor, in Ann Arbor, Michigan.
In this interview, Ruotolo answers the following questions:
- Would you explain in basic terms what the focus of your research was in your recent Analyst journal paper on ion mobility-mass spectrometry, and why this research is important?
- Why is ion mobility (IM) resolution currently insufficient for detecting structural differences in large biomolecules?
- How did you investigate the reproducibility of collision-induced unfolding (CIU) data, and what techniques did you use?
- What is the significance of using CIU data when performing native ion mobility-mass spectrometry (IM–MS) research?
- Could you elaborate on the challenges that you faced in this study, particularly when it came to addressing differences in the CIU50 values?
- Based on your findings, what implications do you think this research has for future biomolecular classification efforts?
Our interview with Ruotolo was one of several conducted live at ASMS 2023. Stay tuned for our other interviews conducted at ASMS.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
